Quantitative analysis of bone marrow fibrosis highlights heterogeneity in myelofibrosis and augments histological assessment: An Insight from a phase II clinical study of zinpentraxin alfa

Hemasphere. 2024 Jun 13;8(6):e105. doi: 10.1002/hem3.105. eCollection 2024 Jun.

Hosuk Ryou¹, Korsuk Sirinukunwattana², Ruby Wood³, Alan Aberdeen², Jens Rittscher^{2

3

4

5

6}, Olga K Weinberg⁷, Robert Hasserjian⁸, Olga Pozdnyakova⁹, Frank Peale¹⁰, Brian Higgins¹⁰, Pontus Lundberg¹¹, Kerstin Trunzer¹¹, Claire N Harrison¹², Daniel Royston¹³

¹ Nuffield Department of Medicine University of Oxford Oxford UK.
² Ground Truth Labs, Ltd. Oxford UK.
³ Institute of Biomedical Engineering (IBME), Department of Engineering Science University of Oxford Oxford UK.
⁴ Big Data Institute/Li Ka Shing Centre for Health Information and Discovery University of Oxford Oxford UK.
⁵ Oxford NIHR Biomedical Research Centre Oxford University Hospitals NHS Foundation Trust Oxford UK.
⁶ Ludwig Institute for Cancer Research University of Oxford Oxford UK.
⁷ Department of Pathology University of Texas Southwestern Medical Center Dallas Texas USA.
⁸ Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.
⁹ Department of Pathology and Laboratory Medicine University of Pennsylvania Philadelphia Pennsylvania USA.
¹⁰ Genentech, Inc. South San Francisco California USA.
¹¹ F. Hoffmann-La Roche, Ltd. Basel Switzerland.
¹² Guy's & St Thomas' NHS Foundation Trust London UK.
¹³ Nuffield Division of Clinical Laboratory Sciences (NDCLS), Radcliffe Department of Medicine University of Oxford Oxford UK.

No abstract available